The advantage of a pharmaceutically induced mild SMA model in the Li SMA mice is their favorable breeding scheme with 50% of their progeny exhibiting symptomatology due to pathologically low levels of the SMN protein. Here, SMN2 is linked to proximal spinal muscular atrophy.